CRMD

CorMedix Inc.

39
Fundamentals55/ 100
Valuation37/ 100
Upside potential33/ 100
Risk potential61/ 100

CRMD's fundamentals are mixed, but it looks expensive: trading at 6.6x earnings, above its usual 3.9x. Analysts expect a turn to a loss, though they disagree widely on how much.

CRMD Fundamentals

MetricStatus
Healthy
Healthy
Strong
Strong

CRMD's revenue, profitability, cash flow and balance sheet are all currently healthy.

CRMD PE Valuation

CHEAPFAIREXPENSIVE15x30x45x61x
CHEAPFAIREXPENSIVE15x30x45x61x
LevelPEPriceVs current
Cheap3.5x$2.52-48%
Fair3.9x$2.83-41%
Current6.6x$4.84—
Expensive18x$13.42+177%

Historical ranges are pointers, not guarantees.

CRMD's PE is in its expensive range at 6.6x.

CRMD Forward outlook

MetricOutlook
--
Turning to a loss
Strong decline
Strongly weakening
Limited
Low

Analysts expect CRMD's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.

CRMD Risk to reward

ScenarioChangePrice
Upside+30%$6.30
Downside-61%$1.89

Calculated from the latest close: $4.84 on Nov 12.

CRMD's one-year downside scenario is about twice its upside: −61% against +30%.

CRMD Earnings Per Share

Q4 2023: $-0.91Q1 2024: $-0.92Q2 2024: $-0.92Q3 2024: $-0.80Q4 2024: $-0.30Q1 2025: $0.25Q2 2025: $0.78Q3 2025: $2.09Q4 2025: $2.04Q1 2026: $2.17Q2 2026: $2.18Q3 2026: $0.73
Q4 2023: $-0.91Q1 2024: $-0.92Q2 2024: $-0.92Q3 2024: $-0.80Q4 2024: $-0.30Q1 2025: $0.25Q2 2025: $0.78Q3 2025: $2.09Q4 2025: $2.04Q1 2026: $2.17Q2 2026: $2.18Q3 2026: $0.73
QuarterTTM EPSYoY
Q3 2026$0.73-65%
Q2 2026$2.18+179%
Q1 2026$2.17+768%
Q4 2025$2.04+$2.34
Q3 2025$2.09+$2.89
Q2 2025$0.78+$1.70
Q1 2025$0.25+$1.17
Q4 2024-$0.30+$0.61

CRMD earned $0.73 per share over the past year, down 65% from the year before.

CRMD Quarterly Revenue

Q4 2023: --Q1 2024: --Q2 2024: $806,119Q3 2024: $11MQ4 2024: $31MQ1 2025: $39MQ2 2025: $40MQ3 2025: $104MQ4 2025: $129MQ1 2026: $127MQ2 2026: $102MQ3 2026: $55M
Q4 2023: --Q1 2024: --Q2 2024: $806,119Q3 2024: $11MQ4 2024: $31MQ1 2025: $39MQ2 2025: $40MQ3 2025: $104MQ4 2025: $129MQ1 2026: $127MQ2 2026: $102MQ3 2026: $55M
QuarterRevenueYoY
Q3 2026$54.5M-48%
Q2 2026$101.9M+157%
Q1 2026$127.4M+226%
Q4 2025$128.6M+312%
Q3 2025$104.3M+810%
Q2 2025$39.7M+4829%
Q4 2022$29.7K-47%
Q3 2022$6.8K-82%

CRMD's revenue is growing: $55M last quarter, down 48% from the same quarter a year ago.

CRMD Free Cash Flow

Q4 2023: −$11MQ1 2024: −$17MQ2 2024: −$14MQ3 2024: −$14MQ4 2024: −$6MQ1 2025: $20MQ2 2025: $30MQ3 2025: $30MQ4 2025: $93MQ1 2026: $42MQ2 2026: $86MQ3 2026: $88M
Q4 2023: −$11MQ1 2024: −$17MQ2 2024: −$14MQ3 2024: −$14MQ4 2024: −$6MQ1 2025: $20MQ2 2025: $30MQ3 2025: $30MQ4 2025: $93MQ1 2026: $42MQ2 2026: $86MQ3 2026: $88M
QuarterFree cash flowYoY
Q3 2026$87.8M+189%
Q2 2026$85.7M+186%
Q1 2026$41.7M+111%
Q4 2025$92.7M+$98.4M
Q3 2025$30.4M+$44M
Q2 2025$30M+$44M
Q1 2025$19.7M+$37.1M
Q4 2024-$5.6M+$5.4M

CRMD has burned cash in most quarters: $308M over the past year, about four times what it generated the year before.

CRMD Total Shares

Q4 2023: 51MQ1 2024: 58MQ2 2024: 58MQ3 2024: 59MQ4 2024: 59MQ1 2025: 69MQ2 2025: 72MQ3 2025: 86MQ1 2026: 93MQ2 2026: 92MQ3 2026: 78M
Q4 2023: 51MQ1 2024: 58MQ2 2024: 58MQ3 2024: 59MQ4 2024: 59MQ1 2025: 69MQ2 2025: 72MQ3 2025: 86MQ1 2026: 93MQ2 2026: 92MQ3 2026: 78M
PeriodChange %Net change
Quarterly-15%-14M shares
1 year+9.1%+6.5M shares
3 years+73%+33.1M shares
5 years+106%+40.4M shares
Available history+225%+54.3M shares

CRMD has 78M diluted shares, up 9.1% from a year ago.

CRMD Net Leverage

Q1 2025: -4.5xQ2 2025: -3.2xQ3 2025: -0.5xQ4 2025: -0.9xQ1 2026: -0.8xQ2 2026: -1.0xQ3 2026: -1.8x
Q1 2025: -4.5xQ2 2025: -3.2xQ3 2025: -0.5xQ4 2025: -0.9xQ1 2026: -0.8xQ2 2026: -1.0xQ3 2026: -1.8x
QuarterNet LeverageStatus
Q3 2026-1.8xNet Cash
Q2 2026-1.0xNet Cash
Q1 2026-0.8xNet Cash
Q4 2025-0.9xNet Cash
Q3 2025-0.5xNet Cash
Q2 2025-3.2xNet Cash
Q1 2025-4.5xNet Cash

CRMD has more cash than debt.

CRMD Weekly Momentum

MetricValueStatus
RSI29.4Oversold
Stochastic2.7Oversold

CRMD's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).

CRMD PE vs Healthcare Sector

MetricCRMDSector medianRelative
PE6.6x26x74% below
PE %662937 pts above

CRMD is trading at 6.6x earnings, a 74% discount to the Healthcare sector's median of 26x.

CRMD Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$6.6727% below
20 week MA$7.4935% below
50 week MA$7.9139% below
100 week MA$9.4149% below
200 week MA$7.2233% below

CRMD is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.

CRMD Yearly ROI

YearStart priceEnd priceROI
2020$7.14$7.87+10%
2021$7.87$4.98-37%
2022$4.98$4.11-17%
2023$4.11$3.76-8.5%
2024$3.76$8.21+118%
2025$8.21$12.5+53%
2026 YTD$12.5$4.84-61%

CRMD has finished lower in three of the last six years. It's down 61% so far in 2026.

Give your agent the market.

Get API key